Pfizer's latest $10 billion buyback suggests scant interest in deals
This article was originally published in Scrip
Executive Summary
Since taking over as CEO in December 2010, Pfizer’s Ian Read has made his view on stock buybacks very clear: Buying back Pfizer’s own stock is a better use of the company’s cash than doing acquisitions.